Articles - Parkinson's Disease and Treatment

Recent articles to be released shortly in Volume-7

Open Access Short Communication Article ID: OJPDT-5-112

The results of a clinical and neurophysiological study of the effectiveness of Parkon spray in the treatment of Parkinson’s Disease (PD)

10.17352/ojpdt.000012

Published On: October 04, 2022 | Pages: 001 - 003

Author(s): Gekht BM and Goldstein NI*

For more than 25 years, we have begun an experimental study of the physiological effect of micromolar concentrations of reactive oxygen species on the regulatory functions of the central nervous system. We found that these effects extend to the CNS centers and hormonal regulation of the hypothalamus and pituitary gland [1-4], as well as in the control of BBB permeabil ... CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat

Abstract View Full Article View

Open Access Research Article Article ID: OJPDT-4-111

Multi-center clinical study of Parkon® efficiency

10.17352/ojpdt.000011

Published On: October 29, 2021 | Pages: 005 - 009

Author(s): Fjodorova NE, Shtok VH, Gusev EI and Naum Goldstein*

The purpose of the study was to investigate the efficacy of Parkon® spray as the compound for the effect on motor disturbances in treatment of both Parkinson’s Disease (PD) and neuroleptic-induced Parkinsonism. The main active ingredient of Parkon® is low concentrated hydrogen peroxide [1-3]. ... CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat

Abstract View Full Article View

Open Access Perspective Article ID: OJPDT-4-110

How does medicine Parkon® affect the MPTP-induced oxidation stress and MAO systems of the rats brain

10.17352/ojpdt.000010

Published On: May 25, 2021 | Pages: 001 - 004

Author(s): N Goldstein*, A Kamensky, T Arshavskaya and R Goldstein

The review of the literature seems to confirm effects of negative air ions (NAIs) on several brain functions. Indeed, a significant association between NAIs exposure and both wellbeing and high cognitive performances has been described [1-3]. ... CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat

Abstract View Full Article View

Open Access Mini Review Article ID: OJPDT-3-109

Cardiac Effects of Parkinson’s Diseasec

10.17352/ojpdt.000009

Published On: December 19, 2020 | Pages: 006 - 007

Author(s): Hüsnü Değirmenci*, Eftal Murat Bakirci and Hikmet Hamur

Parkinson’s disease, which has symptoms and signs such as tremor, bradykinesia, rigidity and postural instability, is the most common neurodegenerative disease after Alzheimer’s disease. In Parkinson’s disease, pathological mechanisms such as abnormal accumulation of protein aggregates, disruption of protein clearance pathways, oxidative stress, neuroinflammation, mit ... CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat

Abstract View Full Article View

Open Access Research Article Article ID: OJPDT-3-108

Parkon® in the treatment of multiple sclerosis. A pilot study

10.17352/ojpdt.000008

Published On: August 07, 2020 | Pages: 001 - 005

Author(s): Goldstein NI, Golubev VL and Goldstein RN*

Multiple Sclerosis (MS) is one of the most common chronic demyelinating diseases of the central nervous system. The disease affects and relatively quickly leads to disability in mainly people 15-40 years of age. The development of MS can occur progressively or with exacerbations and remissions. The pathogenesis of the disease is based on an autoimmune process directed ... CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat

Abstract View Full Article View